Technology hurdles of in vivo gene editing therapy

GenEditBio has multiple technology platforms to tackle bottlenecks restricting in vivo gene editing therapy.


Novel Cas nucleases mining and optimization

A systematic approach to mine novel Cas nucleases in nature and follow up with extensive characterization and optimizations, expanding our toolbox with novel, potent, precise, small and diverse nucleases.

Lead Editor

A new editing system broadens sequence correction types beyond single-base transitions and allows for versatile sequence manipulations to correct most known genetic alterations in human diseases.

Development of next generation delivery tools

Novel gene delivery tools for transient and effective gene editing reagent delivery, minimizing off-target effects and improving desired tissue-targeting specificities.